Entrepreneurial scientist set to advance knowledge, efficacy and safety of medical cannabis
OTTAWA, Nov. 6, 2017 /CNW/ - National Access Cannabis Corp. ("NAC" or the "Company") (TSX VENTURE: NAC), Canada's best practices leader in delivering secure, safe, and responsible access to legal medical cannabis today announced that Dr. Tyler Wish has joined the Company to establish and lead its research and development division. In this executive role, Dr. Wish will be responsible for furthering the Company's efforts to advance knowledge of medicinal cannabis as a pharmaceutical product and to enhance its efficacy and safety across multiple patient populations.
"Dr. Wish's extensive entrepreneurial experience and scientific background will be an important catalyst in driving NAC's involvement in advancing the medicinal cannabis market through greater scientific and technological opportunities," said Mark Goliger, Chief Executive Officer of National Access Cannabis. "As much excitement as there is for the future of Canada's recreational cannabis market, the global market for cannabis-related science and technology offers even greater opportunities. Tyler's initial focus will be on establishing research programs to investigate the clinical utility of medicinal cannabis for treating PTSD and Diabetes, both of which affect a large number of Canadians, particularly Veterans and Indigenous groups with whom NAC has established important partnerships."
"NAC has supported over 10,000 patients to date, helping them to source, select and use legal medical cannabis in treatment of their chronic and acute conditions," said Dr. Tyler Wish. "With this established and trusted partnership between patients and physicians, NAC has a unique opportunity and responsibility to take a leadership position with respect to generating data, knowledge and insights that lead to improving human health through the use of medicinal cannabis."
Dr. Tyler Wish is a trained clinical/molecular epidemiologist, as well as an accomplished entrepreneur and life-science executive who was recently recognized and appointed as 1 of 10 "Canadian Innovation Leaders" by the Federal Minister of Innovation, Science and Economic Development. Prior to joining NAC, Tyler was a founder and the Chief Executive Officer of Sequence Bio, a privately-held biotechnology company that lead a large-scale human genome sequencing initiative designed to support genetic-driven drug discovery and precision medicine.
The Company also announced today that it has retained LodeRock Advisors Inc. ("LodeRock") for strategic investor relations and capital markets communications services. Under the terms of the Investor Relations agreement, NAC will pay LodeRock a monthly fee of CAD $8,000 for ongoing strategic communication services. Neither LodeRock nor its principals presently have any other direct or indirect interest in NAC securities.
LodeRock Advisors is a group of senior capital markets communications executives who develop and execute communications programs in order to help companies achieve their capital markets objectives and capture the full potential of their public listing. The engagement of LodeRock remains subject to the approval of the TSX Venture Exchange.
About National Access Cannabis
National Access Cannabis is Canada's best practices leader in delivering secure, safe, and responsible access to legal medical cannabis. NAC enables patients to gain knowledge and the legal medical documentation required to navigate Canada's disparate network of authorized Licensed Producers of Cannabis. Through its Canada-wide network of care centres, NAC has partnered with health professionals to improve the quality of life of its local members and provide services designed to inform, educate and supply expert advice.
National Access Cannabis Corp. is listed on the TSX Venture Exchange under the symbol (TSXV: NAC).
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE National Access Cannabis Corp.
For further information: Investor Relations, Robert Kelly, LodeRock Advisors Inc., (416) 992-4539, email@example.com